GSK is trimming its global research and development workforce. Up to 350 employees across the U.S. and U.K. will be affected by these changes. The company stated it is reallocating resources to key priorities and investing in technology. GSK also plans to boost its R&D budget and accelerate dr-g discovery.
The dr-gmaker intends to invest $30 billion in U.S. R&D and supply chain infrastructure over five years.
https://www.fiercebiotech.com/biotech/gsk-plans-lay-350-rd-workers-across-us-uk